Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Medicus Pharma partners with Pfizer for SkinJect co-development and licensing.

Sep 12, 2026•about 2 hours ago

Contract Type

partnership

TorontoBiotechnologyHealthcareTherapeutics

Description

Medicus Pharma has entered a partnership with Pfizer to co-develop a CD228-targeted antibody-drug conjugate. This partnership includes $2 million in development funding, aimed at enhancing treatments for melanoma and solid tumors.

Company Information

Company

Medicus Pharma

Location

100 KING STREET WEST

Toronto, Ontario, Canada

About

Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC). Medicus is also developing Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer. D-MNA and Teverelix, collectively represent ~$8 billion in potential market opportunity.

Related People

Suggested for you
Raza
Likely contact at this company
••••••••@••••••••

See Raza's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Medicus Pharma's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Medicus Pharma signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.